Breast CancerINSEMANCT02466737
Comparison of Axillary Sentinel Lymph Node Biopsy Versus no Axillary Surgery
A study testing no axillary surgery versus SLNB and SLNB versus completion ALND in people with Breast Cancer, run by University of Rostock at 150 sites in 2 countries.
Trial summary
Although there is no doubt that the presence of lymph node metastases worsens prognosis of a patient, unambiguous evidence to support lymph node dissection is still lacking. For many solid tumors, the role of lymph node dissection is yet controversial, and may depend on the tumor type and the stage of patient… Read more about this study
- Who is it for?
- Ages 18 years and older, women only
- Conditions the study is for
- Breast Cancer
- What is being tested?
- no axillary surgery versus SLNB and SLNB versus completion ALND
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 5,505 participants
- Where
- 150 sitesin 2 countries
- Study dates
- Sep 2015to Dec 2029
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Written informed consent prior to beginning breast-conserving surgery, including expected cooperation of the patients for follow-up, must be obtained and documented according to the local regulatory requirements
- Histologically confirmed unilateral primary invasive carcinoma of the breast (core biopsy or open biopsy). Multifocal or multicentric tumors are allowed if breast-conserving surgery is planned
- Age at diagnosis at least 18 years
- Preoperative imaging techniques with estimated tumor size of <5 cm (iT1/iT2 irrespective of hormone sensitivity or HER2 status)
- Clinically and sonographically tumor-free axilla prior to core biopsy (cN0/iN0)
- In cases with cN0 and iN+, a negative core biopsy or fine needle aspiration (FNA) biopsy of the sonographically suspected lymph node is required before randomization
- No clinical evidence for distant metastasis (M0)
- Planned breast-conserving surgery (R0 resection) with postoperative external whole-breast irradiation (conventional fractionation or hypofractionation)
Who cannot join
- History of malignancy within last 5 years, except curatively treated basalioma of the skin and carcinoma in situ of the cervix
- Time since core biopsy >3 months (optimal <1 month)
- Previous and already (neoadjuvant) treated invasive breast carcinoma
- Histologically non-invasive breast carcinoma
- cT3/T4 or iT3/T4 tumors
- pregnant or lactating patients
Show all 9Show fewer
- Planned total mastectomy (e.g. multicentric tumors )
- Planned intraoperative radiotherapy (e.g. Intrabeam) or postoperative partial breast irradiation (e.g. multicatheter technique) alone; both procedures are allowed as boost techniques
- Male patients
Trial locations and contacts
150 sites in 2 countries.
150 sites in 2 countries
Germany142 sites
Ostalb-Klinikum, Brustzentrum Aalen
Aalen, Baden-Wurttemberg, 73430
Klinikum St. Marien
Amberg, Bavaria, 92224
AN regiomed Klinikum Ansbach
Ansbach, Bavaria, 91522
Klinikum Aschaffenburg
Aschaffenburg, Bavaria, 63739
Hämatologisch-onkologische Praxis
Augsburg, Bavaria, 86150
Hufeland-Klinik Bad Langensalza
Bad Langensalza, Thuringia, 99947
Caritas-Krankenhaus Brustzentrum Tauberfranken
Bad Mergentheim, Baden-Wurttemberg, 97980
Klinikum Mittelbach Brustzentrum
Baden-Baden, Baden-Wurttemberg, 76532
Klinikum Bayreuth GmbH, Frauenklinik
Bayreuth, Bavaria, 95445
Charite Campus Mitte
Berlin, State of Berlin, 10117
Sana Klinikum Berlin-Lichtenberg
Berlin, State of Berlin, 10365
St. Gertrauden Krankenhaus
Berlin, State of Berlin, 10713
DRK Kliniken Köpenick
Berlin, State of Berlin, 12559
Park-Klinik Weißensee
Berlin, State of Berlin, 13086
Evang. Waldkrankenhaus Spandau
Berlin, State of Berlin, 13589
DRK-Kliniken Westend
Berlin, State of Berlin, 14050
Krankenhaus Waldfriede
Berlin, State of Berlin, 14163
Sana-Klinikum Biberach
Biberach, Baden-Wurttemberg, 88400
Krankenhaus Bietigheim
Bietigheim, Baden-Wurttemberg, 74321
Klinikum Böblingen
Böblingen, Baden-Wurttemberg, 71032
Augusta-Klinik
Bochum, Nordrhein, 44791
Universitätsfrauenklinik Bonn
Bonn, Nordrhein, 53105
Brustzentrum Nordsachsen
Borna, Saxony, 04552
Marienhospital Bottrop
Bottrop, Nordrhein, 46236
Städtisches Klinikum Brandenburg
Brandenburg an der Havel, Brandenburg, 14770
St. Joseph Stift
Bremen, Free Hanseatic City of Bremen, 28209
DIAKO Krankenhaus Bremen
Bremen, Free Hanseatic City of Bremen, 28239
Fürst-Stirum-Klinik
Bruchsal, Baden-Wurttemberg, 76646
Helios Klinikum, Klinik für Gynäkologie
Buch, State of Berlin, 13125
AKH Celle, Brustzentrum
Celle, Lower Saxony, 29223
Uniklinik Köln
Cologne, Nordrhein, 50931
St. Elisabeth Krankenhaus, Brustzentrum
Cologne, Nordrhein, 50935
Carl-Thiem-Klinikum
Cottbus, Brandenburg, 03046
Diakonissenkrankenhaus
Dresden, Saxony, 01099
Krankenhaus St. Joseph-Stift
Dresden, Saxony, 01307
Universität Dresden, Frauenklinik
Dresden, Saxony, 01307
Frauenklinik der H.-Heine-Universität
Düsseldorf, Nordrhein, 40225
Kreisklinik Ebersberg
Ebersberg, Bavaria, 85560
Gynäkologische Praxis
Eggenfelden, Bavaria, 84307
Brustzentrum Donau-Riß
Ehingen, Baden-Wurttemberg, 89584
Universitätsklinikum Essen Frauenklinik
Essen, Nordrhein, 45122
Kliniken Essen-Mitte
Essen, Nordrhein, 45136
Klinikum Esslingen
Esslingen am Neckar, Baden-Wurttemberg, 73730
Sana-Klinik
Eutin, Schleswig-Holstein, 23701
DIAKO Diakonissenkrankenhaus
Flensburg, Schleswig-Holstein, 24939
Agaplesion Markus Krankenhaus
Frankfurt am Main, Hesse, 60431
Universitätsklinikum Brustzentrum
Frankfurt am Main, Hesse, 60590
Klinikum Frankfurt Höchst
Frankfurt am Main, Hesse, 65929
Universitätsklinikum Freiburg
Freiburg im Breisgau, Baden-Wurttemberg, 79106
Frauenklinik Freudenstadt
Freudenstadt, Baden-Wurttemberg, 72250
Klinikum Fürth
Fürth, Bavaria, 90766
Main-Kinzig-Kliniken Gelnhausen
Gelnhausen, Hesse, 63571
Franziskus Hospital Harderberg
Georgsmarienhütte, Lower Saxony, 49124
SRH Waldklinikum
Gera, Thuringia, 07548
Helios Klinikum Gifhorn
Gifhorn, Lower Saxony, 38518
Städtisches Klinikum
Görlitz, Saxony, 02828
Universität Greifswald, Frauenklinik
Greifswald, Mecklenburg-Vorpommern, 17475
Krankenhaus St. Elisabeth und St. Barbara
Halle, Saxony-Anhalt, 06110
Universität Halle/Saale, Frauenklinik
Halle, Saxony-Anhalt, 06120
Universitätsklinikum Hamburg, Brustzentrum
Hamburg, Free and Hanseatic City of Hamburg, 20246
Agaplesion Diakonieklinikum, Brustzentrum
Hamburg, Free and Hanseatic City of Hamburg, 20259
Gynäkologische Praxisklinik Harburg
Hamburg, Free and Hanseatic City of Hamburg, 21673
Albertinen-Krankenhaus, Brustzentrum
Hamburg, Free and Hanseatic City of Hamburg, 22457
Klinikum Hanau GmbH
Hanau, Hesse, 63450
Henriettenstiftung Frauenklinik
Hanover, Lower Saxony, 30559
Vinzenzkrankenhaus Hannover
Hanover, Lower Saxony, 30559
MHH Frauenklinik
Hanover, Lower Saxony, 30625
Altmark-Klinikum Brustzentrum
Hansestadt Salzwedel, Saxony-Anhalt, 29410
Universitätsklinikum Heidelberg
Heidelberg, Baden-Wurttemberg, 69120
Kreiskrankenhaus Bergstraße gGmbH
Heppenheim an der Bergstrasse, Hesse, 64646
St. Bernward Krankenhaus
Hildesheim, Lower Saxony, 31134
Universitätsklinikum Jena
Jena, Thuringia, 07747
Westpfalz Klinikum
Kaiserslautern, Rhineland-Palatinate, 67655
Städtisches Klinikum Karlsruhe
Karlsruhe, Baden-Wurttemberg, 76133
ViDia Christliche Kliniken, Diakonissenkrankenhaus Karlsruhe
Karlsruhe, Baden-Wurttemberg, 76199
Elisabeth Krankenhaus Kassel
Kassel, Hesse, 34117
Klinikum Kassel
Kassel, Hesse, 34125
Klinikum Kempten-Oberallgäu
Kempten (Allgäu), Bavaria, 87439
Universitätsklinikum Schleswig-Hostein
Kiel, Schleswig-Holstein, 24105
BZ Mittelrhein Koblenz+Mayen
Koblenz, Rhineland-Palatinate, 56073
Klinikum Landshut
Landshut, Bavaria, 84034
Universitätsklinikum Leipzig, Brustzentrum
Leipzig, Saxony, 04103
St. Elisabeth Krankenhaus
Leipzig, Saxony, 04277
Bonifatius-Hospital, Brustzentrum
Lingen, Lower Saxony, 49808
St. Elisabethen Krankenhaus
Loerrach, Baden-Wurttemberg, 79539
Universitätsklinikum Schleswig-Holstein, Campus Lübeck
Lübeck, Schleswig-Holstein, 23538
Klinikum Märkische Kliniken, Brustzentrum
Lüdenscheid, Nordrhein, 58515
Klinikum Ludwigsburg
Ludwigsburg, Baden-Wurttemberg, 71640
Ev. Krankenhaus, Frauenklinik
Ludwigsfelde, Brandenburg, 14974
Klinikum Ludwigshafen
Ludwigshafen am Rhein, Rhineland-Palatinate, 67063
Klinikum Lünen, Brustzentrum
Lünen, Nordrhein, 44534
Klinik St. Marienstift
Magdeburg, Saxony-Anhalt, 39110
Klinikum Fichtelgebirge gGmbH, Brustzentrum
Marktredwitz, Bavaria, 95615
Helios Klinikum Meiningen, Brustzentrum
Meiningen, Thuringia, 98617
Klinikum Memmingen
Memmingen, Bavaria, 87700
Klinikum der Universität München
München, Bavaria, 80337
Klinikum Harlaching, Frauenklinik
München, Bavaria, 81545
St. Franziskus-Hospital
Münster, Nordrhein, 48145
Universitätsklinikum Münster
Münster, Nordrhein, 48149
Dietrich Bonhoeffer Klinikum, Brustzentrum
Neubrandenburg, Mecklenburg-Vorpommern, 17036
Euregio-Klinik Brustzentrum Nordhorn
Nordhorn, Lower Saxony, 48527
Agaplesion Ev. Klinikum, Brustzentrum Schaumburg
Obernkirchen, Lower Saxony, 31683
Sana Klinikum Offenbach
Offenbach, Hesse, 63069
Klinikum Osnabrück
Osnabrück, Lower Saxony, 49076
Klinikum Passau
Passau, Bavaria, 94032
Helios Klinik Pforzheim
Pforzheim, Baden-Wurttemberg, 75175
Siloah St. Trudpert Klinikum
Pforzheim, Baden-Wurttemberg, 75179
Klinikum Ernst von Bergmann
Potsdam, Brandenburg, 14467
Frauenklinik der Universität Regensburg, Caritas-Krankenhaus St. Josef
Regensburg, Bavaria, 93053
Klinikum am Steinenberg
Reutlingen, Baden-Wurttemberg, 72764
Klinikum Obergöltzsch Rodewisch
Rodewisch, Saxony, 08228
Universitäts-Frauenklinik
Rostock, Mecklenburg-Vorpommern, 18059
Diakoniekrankenhaus, Frauenklinik
Rotenburg (Wümme), Lower Saxony, 27356
Helios Klinik Rottweil
Rottweil, Baden-Wurttemberg, 78628
Helios Klinik
Schkeuditz, Saxony, 04435
Rems-Murr Klinik
Schorndorf, Baden-Wurttemberg, 73614
Helios Kliniken Schwerin
Schwerin, Mecklenburg-Vorpommern, 19049
Marienkrankenhaus
Schwerte, Nordrhein, 58239
St. Marienkrankenhaus, Frauenklinik
Siegen, Nordrhein, 57072
DRK Krankenhaus, Brustzentrum
Sömmerda, Thuringia, 99610
Diakonissen-Stiftungs-Krankenhaus Speyer
Speyer, Rhineland-Palatinate, 67346
Klinikum Starnberg
Starnberg, Bavaria, 82319
Johanniter-Krankenhaus, Frauenklinik
Stendal, Saxony-Anhalt, 39576
SRH Zentralklinikum Suhl
Suhl, Thuringia, 98527
Klinikum Traunstein
Traunstein, Bavaria, 83278
St. Josef-Hospital, BZ Rhein-Sieg
Troisdorf, Nordrhein, 53840
Universitätsfrauenklinik
Tübingen, Baden-Wurttemberg, 72076
Klinikum Tuttlingen
Tuttlingen, Baden-Wurttemberg, 78532
Universitätsfrauenklinik Ulm
Ulm, Baden-Wurttemberg, 89075
Katharinen-Hospital, Brustzentrum
Unna, Nordrhein, 59423
Schwarzwald-Baar Klinikum
Villingen-Schwenningen, Baden-Wurttemberg, 78050
Kliniken Nordoberpfalz AG, Brustzentrum Weiden
Weiden, Bavaria, 92637
Harzklinikum, Brustzentrum Harz
Wernigerode, Saxony-Anhalt, 38855
Marien-Hospital
Wesel, Nordrhein, 46483
St. Josefs-Hospital, Frauenklinik
Wiesbaden, Hesse, 65189
Asklepios Paulinenklinik
Wiesbaden, Hesse, 65197
Helios Dr. Horst Schmidt Klinikum
Wiesbaden, Hesse, 65199
Rems-Murr Kliniken
Winnenden, Baden-Wurttemberg, 71364
Klinikum Wolfsburg, Frauenklinik
Wolfsburg, Lower Saxony, 38440
Stadtkrankenhaus Worms
Worms, Rhineland-Palatinate, 67550
Rotkreuzklinik Würzburg
Würzburg, Bavaria, 97070
Klinikum Mitte, Missio Brustzentrum
Würzburg, Bavaria, 97074
Austria8 sites
BGZ Dornbirn, Gynäkologie
Dornbirn, 6850
LKH Uni-Klinikum Graz, Gynäkologie
Graz, 8036
Ordensklinikum-BHS
Linz, 4010
Kepler Universitätsklinikum
Linz, 4020
KH der Barmherzigen Brüder
Saint Veit/Glan, 9300
Universitätsfrauenklinik Salzburg
Salzburg, State of Salzburg, 5020
Hanusch-Krankenhaus, Brustzentrum
Vienna, 1140
Landes-Krankenhaus Wolfsberg, Chirurgie
Wolfsberg, 9400
About this study
Official title: Comparison of Axillary Sentinel Lymph Node Biopsy Versus no Axillary Surgery in Patients With Early-stage Invasive Breast Cancer and Breast-conserving Surgery: a Randomized Prospective Surgical Trial. Intergroup-Sentinel-Mamma (INSEMA)-Trial
Although there is no doubt that the presence of lymph node metastases worsens prognosis of a patient, unambiguous evidence to support lymph node dissection is still lacking. For many solid tumors, the role of lymph node dissection is yet controversial, and may depend on the tumor type and the stage of patient presentation for diagnosis. Axillary surgery for breast cancer is now considered as staging procedure that does not seem to influence breast cancer mortality. Women with breast cancer have benefitted greatly from a series of carefully performed randomized controlled trial focusing on axillary surgery. The objective of INSEMA is to show that less axillary surgery is better, in that oncological outcomes are the same and less surgical intervention will result in fewer surgical complications.
Read the detailed description
Currently, axillary surgery for breast cancer is considered as staging procedure that does not seem to influence breast cancer mortality, since the risk of developing metastasis depends mainly on the biological behaviour of the primary (seed-and-soil model). Based on this, the postsurgical therapy should be considered on the basis of biologic tumor characteristics rather than nodal involvement.
The goal of the present study is to show that early-stage breast cancer patients with reduced extent of axillary surgery are not inferior regarding disease-free survival outcome compared with the standard arm. All patients will be first randomized to either no axillary surgical intervention or axillary sentinel lymph node biopsy (SLNB). Patients with SLNB and pN+(sn) status will be secondly randomized to either SLNB alone or completion axillary lymph node dissection (ALND) in cases with less than four involved nodes (1-3 macrometastases). Patients with four or more metastatic sentinel lymph nodes should undergo completion ALND.
Postoperative systemic treatment should be based on local multidisciplinary tumor board recommendation according to the current German AGO and S3 guidelines. For women who are treated with breast-conserving surgery, the most common site of local recurrence is the conserved ipsilateral breast itself. Thus, whole-breast radiation therapy after breast-conserving surgery is mandatory and should be performed according to the current guidelines (S3, AGO, DEGRO).
During follow-up, patients will be assessed for disease recurrence according to standard clinical practice. History and physical examination will be performed every 6 months for the first 36 months and yearly thereafter. Annual mammography and sonography will be required; other testing will be based on symptoms and investigator preference. The total number of patients to be randomized into the trial will be approximately 7,095. An event-driven final efficacy analysis will be performed per-protocol for two primary objectives.
- Conditions
- Breast Cancer
- Being tested
- no axillary surgery versus SLNB, SLNB versus completion ALND
- Keywords
- axillary surgery, sentinel lymph node biopsy
- Medical subject headings
- Breast Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
no axillary surgery versus SLNBProcedure or surgery
in cases with newly diagnosed breast cancer and clinically negative axillary status
SLNB versus completion ALNDProcedure or surgery
in cases with 1-3 macrometastases in sentinel lymph nodes
| Study group | Role | What they receive |
|---|---|---|
| no axillary surgery | Experimental | Not described Receives: Procedure: no axillary surgery versus SLNB |
| sentinel lymph node biopsy | Active comparator | standard arm in first randomization Receives: Procedure: no axillary surgery versus SLNB |
| sentinel lymph node biopsy alone | Experimental | Not described Receives: Procedure: SLNB versus completion ALND |
| completion axillary lymph node dissection | Active comparator | standard arm in second randomization Receives: Procedure: SLNB versus completion ALND |
What is being measured
The primary outcome is the main question the study is designed to answer.
invasive disease-free survival (IDFS) after breast-conserving surgery
non-inferiority question
Measured: 5 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Jun 2015 (estimated)
- Study startSep 2015
- Primary completion30 Aug 2024
- Study completionDec 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (6)Papers the sponsor has linked to this study.
- Other trials for Breast CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Enrolment
- 5,505 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Rostock
- Sponsor type
- University, hospital or other
- Collaborators
- German Cancer Aid, GBG Forschungs GmbH
- Responsible party
- Principal investigator, Toralf Reimer, MD PhD, University of Rostock
- Investigators
- Toralf Reimer, MD, PhD, Study chair, University Medical Center Rostock
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02466737
- Sponsor's protocol ID
- GBG 75 / ABCSG 43
- Acronym
- INSEMA
- Status last verified
- Apr 2026
- First submitted
- 4 Jun 2015
- Last updated
- 1 May 2026
- Results posted
- No
- Data monitoring committee
- Yes
Publications
Reimer T, Stachs A, Nekljudova V, Loibl S, Hartmann S, Wolter K, Hildebrandt G, Gerber B. Restricted Axillary Staging in Clinically and Sonographically Node-Negative Early Invasive Breast Cancer (c/iT1-2) in the Context of Breast Conserving Therapy: First Results Following Commencement of the Intergroup-Sentinel-Mamma (INSEMA) Trial. Geburtshilfe Frauenheilkd. 2017 Feb;77(2):149-157. doi: 10.1055/s-0042-122853.
PubMed 28331237Hildebrandt G, Stachs A, Gerber B, Potenberg J, Krug D, Wolter K, Kuhn T, Zierhut D, Sedlmayer F, Kaiser J, Reitsamer R, Heil J, Nekljudova V, Bekes I, Loibl S, Reimer T. Central Review of Radiation Therapy Planning Among Patients with Breast-Conserving Surgery: Results from a Quality Assurance Process Integrated into the INSEMA Trial. Int J Radiat Oncol Biol Phys. 2020 Jul 15;107(4):683-693. doi: 10.1016/j.ijrobp.2020.04.042. Epub 2020 May 11.
PubMed 32437921Reimer T, Stachs A, Veselinovic K, Polata S, Muller T, Kuhn T, Heil J, Ataseven B, Reitsamer R, Hildebrandt G, Knauer M, Golatta M, Stefek A, Zahm DM, Thill M, Nekljudova V, Krug D, Loibl S, Gerber B; INSEMA investigators. Patient-reported outcomes for the Intergroup Sentinel Mamma study (INSEMA): A randomised trial with persistent impact of axillary surgery on arm and breast symptoms in patients with early breast cancer. EClinicalMedicine. 2022 Nov 25;55:101756. doi: 10.1016/j.eclinm.2022.101756. eCollection 2023 Jan.
PubMed 36457648Marme F, Krieghoff-Henning E, Gerber B, Schmitt M, Zahm DM, Bauerschlag D, Forstbauer H, Hildebrandt G, Ataseven B, Brodkorb T, Denkert C, Stachs A, Krug D, Heil J, Golatta M, Kuhn T, Nekljudova V, Gaiser T, Schonmehl R, Brochhausen C, Loibl S, Reimer T, Brinker TJ. Deep learning to predict breast cancer sentinel lymph node status on INSEMA histological images. Eur J Cancer. 2023 Dec;195:113390. doi: 10.1016/j.ejca.2023.113390. Epub 2023 Oct 18.
PubMed 37890350Reimer T, Stachs A, Veselinovic K, Kuhn T, Heil J, Polata S, Marme F, Muller T, Hildebrandt G, Krug D, Ataseven B, Reitsamer R, Ruth S, Denkert C, Bekes I, Zahm DM, Thill M, Golatta M, Holtschmidt J, Knauer M, Nekljudova V, Loibl S, Gerber B. Axillary Surgery in Breast Cancer - Primary Results of the INSEMA Trial. N Engl J Med. 2025 Mar 13;392(11):1051-1064. doi: 10.1056/NEJMoa2412063. Epub 2024 Dec 12.
PubMed 39665649Reimer T, Stachs A, Veselinovic K, Kuehn T, Heil J, Polata S, Marme F, Trapp E, Hildebrandt G, Krug D, Ataseven B, Reitsamer R, Ruth S, Denkert C, Bekes I, Stahl N, Thill M, Strittmatter HJ, Mueller T, Golatta M, Zahm DM, Holtschmidt J, Knauer M, Nekljudova V, Loibl S, Gerber B. Axillary surgery in patients with sentinel node macrometastases: secondary results of the randomized INSEMA trial. NPJ Breast Cancer. 2026 Jan 27;12(1):19. doi: 10.1038/s41523-026-00902-7.
PubMed 41593108
Study at a glance
From the registry record, last updated by the sponsor on 1 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparison of Axillary Sentinel Lymph Node Biopsy Versus no Axillary Surgery in Patients With Early-stage Invasive Breast Cancer and Breast-conserving Surgery: a Randomized Prospective Surgical Trial. Intergroup-Sentinel-Mamma (INSEMA)-Trial
- ClinicalTrials.gov ID
- NCT02466737
- Acronym / sponsor ID
- INSEMA / GBG 75 / ABCSG 43
- Conditions
- Breast Cancer
- Keywords
- axillary surgery, sentinel lymph node biopsy
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 5,505 participants (actual)
- Lead sponsor
- University of RostockUniversity, hospital or other
- Collaborators
- German Cancer Aid, GBG Forschungs GmbH
- Study start
- Sep 2015 (actual)
- Primary completion
- 30 Aug 2024 (actual)
- Study completion
- Dec 2029 (estimated)
- First posted
- 9 Jun 2015 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Although there is no doubt that the presence of lymph node metastases worsens prognosis of a patient, unambiguous evidence to support lymph node dissection is still lacking. For many solid tumors, the role of lymph node dissection is yet controversial, and may depend on the tumor type and the stage of patient presentation for diagnosis. Axillary surgery for breast cancer is now considered as staging procedure that does not seem to influence breast cancer mortality. Women with breast cancer have benefitted greatly from a series of carefully performed randomized controlled trial focusing on axillary surgery. The objective of INSEMA is to show that less axillary surgery is better, in that oncological outcomes are the same and less surgical intervention will result in fewer surgical complications.
Detailed description
Currently, axillary surgery for breast cancer is considered as staging procedure that does not seem to influence breast cancer mortality, since the risk of developing metastasis depends mainly on the biological behaviour of the primary (seed-and-soil model). Based on this, the postsurgical therapy should be considered on the basis of biologic tumor characteristics rather than nodal involvement.
The goal of the present study is to show that early-stage breast cancer patients with reduced extent of axillary surgery are not inferior regarding disease-free survival outcome compared with the standard arm. All patients will be first randomized to either no axillary surgical intervention or axillary sentinel lymph node biopsy (SLNB). Patients with SLNB and pN+(sn) status will be secondly randomized to either SLNB alone or completion axillary lymph node dissection (ALND) in cases with less than four involved nodes (1-3 macrometastases). Patients with four or more metastatic sentinel lymph nodes should undergo completion ALND.
Postoperative systemic treatment should be based on local multidisciplinary tumor board recommendation according to the current German AGO and S3 guidelines. For women who are treated with breast-conserving surgery, the most common site of local recurrence is the conserved ipsilateral breast itself. Thus, whole-breast radiation therapy after breast-conserving surgery is mandatory and should be performed according to the current guidelines (S3, AGO, DEGRO).
During follow-up, patients will be assessed for disease recurrence according to standard clinical practice. History and physical examination will be performed every 6 months for the first 36 months and yearly thereafter. Annual mammography and sonography will be required; other testing will be based on symptoms and investigator preference. The total number of patients to be randomized into the trial will be approximately 7,095. An event-driven final efficacy analysis will be performed per-protocol for two primary objectives.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| no axillary surgery | Experimental | Procedure: no axillary surgery versus SLNB |
| sentinel lymph node biopsy | Active comparator | Procedure: no axillary surgery versus SLNBstandard arm in first randomization |
| sentinel lymph node biopsy alone | Experimental | Procedure: SLNB versus completion ALND |
| completion axillary lymph node dissection | Active comparator | Procedure: SLNB versus completion ALNDstandard arm in second randomization |
Who may qualify
- Ages
- 18 years and older
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (8 listed)
- Written informed consent prior to beginning breast-conserving surgery, including expected cooperation of the patients for follow-up, must be obtained and documented according to the local regulatory requirements
- Histologically confirmed unilateral primary invasive carcinoma of the breast (core biopsy or open biopsy). Multifocal or multicentric tumors are allowed if breast-conserving surgery is planned
- Age at diagnosis at least 18 years
- Preoperative imaging techniques with estimated tumor size of <5 cm (iT1/iT2 irrespective of hormone sensitivity or HER2 status)
- Clinically and sonographically tumor-free axilla prior to core biopsy (cN0/iN0)
Key exclusion criteria (9 listed)
- History of malignancy within last 5 years, except curatively treated basalioma of the skin and carcinoma in situ of the cervix
- Time since core biopsy >3 months (optimal <1 month)
- Previous and already (neoadjuvant) treated invasive breast carcinoma
- Histologically non-invasive breast carcinoma
- cT3/T4 or iT3/T4 tumors
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| no axillary surgery versus SLNBin cases with newly diagnosed breast cancer and clinically negative axillary status | Procedure or surgery | no axillary surgery, sentinel lymph node biopsy |
| SLNB versus completion ALNDin cases with 1-3 macrometastases in sentinel lymph nodes | Procedure or surgery | completion axillary lymph node dissection, sentinel lymph node biopsy alone |
Primary outcome
invasive disease-free survival (IDFS) after breast-conserving surgery
Time frame: 5 years
non-inferiority question
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 May 2026.
- Results publication: PubMed 28331237Reimer T, Stachs A, Nekljudova V, Loibl S, Hartmann S, Wolter K, Hildebrandt G, Gerber B. Restricted Axillary Staging in Clinically and Sonographically Node-Negative Early Invasive Breast Cancer (c/iT1-2) in the Context of Breast Conserving Therapy: First Results Following Commencement of the Intergroup-Sentinel-Mamma (INSEMA) Trial. Geburtshilfe Frauenheilkd. 2017 Feb;77(2):149-157. doi: 10.1055/s-0042-122853.
- Results publication: PubMed 32437921Hildebrandt G, Stachs A, Gerber B, Potenberg J, Krug D, Wolter K, Kuhn T, Zierhut D, Sedlmayer F, Kaiser J, Reitsamer R, Heil J, Nekljudova V, Bekes I, Loibl S, Reimer T. Central Review of Radiation Therapy Planning Among Patients with Breast-Conserving Surgery: Results from a Quality Assurance Process Integrated into the INSEMA Trial. Int J Radiat Oncol Biol Phys. 2020 Jul 15;107(4):683-693. doi: 10.1016/j.ijrobp.2020.04.042. Epub 2020 May 11.
- Results publication: PubMed 36457648Reimer T, Stachs A, Veselinovic K, Polata S, Muller T, Kuhn T, Heil J, Ataseven B, Reitsamer R, Hildebrandt G, Knauer M, Golatta M, Stefek A, Zahm DM, Thill M, Nekljudova V, Krug D, Loibl S, Gerber B; INSEMA investigators. Patient-reported outcomes for the Intergroup Sentinel Mamma study (INSEMA): A randomised trial with persistent impact of axillary surgery on arm and breast symptoms in patients with early breast cancer. EClinicalMedicine. 2022 Nov 25;55:101756. doi: 10.1016/j.eclinm.2022.101756. eCollection 2023 Jan.
- Results publication: PubMed 37890350Marme F, Krieghoff-Henning E, Gerber B, Schmitt M, Zahm DM, Bauerschlag D, Forstbauer H, Hildebrandt G, Ataseven B, Brodkorb T, Denkert C, Stachs A, Krug D, Heil J, Golatta M, Kuhn T, Nekljudova V, Gaiser T, Schonmehl R, Brochhausen C, Loibl S, Reimer T, Brinker TJ. Deep learning to predict breast cancer sentinel lymph node status on INSEMA histological images. Eur J Cancer. 2023 Dec;195:113390. doi: 10.1016/j.ejca.2023.113390. Epub 2023 Oct 18.
- Results publication: PubMed 39665649Reimer T, Stachs A, Veselinovic K, Kuhn T, Heil J, Polata S, Marme F, Muller T, Hildebrandt G, Krug D, Ataseven B, Reitsamer R, Ruth S, Denkert C, Bekes I, Zahm DM, Thill M, Golatta M, Holtschmidt J, Knauer M, Nekljudova V, Loibl S, Gerber B. Axillary Surgery in Breast Cancer - Primary Results of the INSEMA Trial. N Engl J Med. 2025 Mar 13;392(11):1051-1064. doi: 10.1056/NEJMoa2412063. Epub 2024 Dec 12.
- Derived from this study: PubMed 41593108Reimer T, Stachs A, Veselinovic K, Kuehn T, Heil J, Polata S, Marme F, Trapp E, Hildebrandt G, Krug D, Ataseven B, Reitsamer R, Ruth S, Denkert C, Bekes I, Stahl N, Thill M, Strittmatter HJ, Mueller T, Golatta M, Zahm DM, Holtschmidt J, Knauer M, Nekljudova V, Loibl S, Gerber B. Axillary surgery in patients with sentinel node macrometastases: secondary results of the randomized INSEMA trial. NPJ Breast Cancer. 2026 Jan 27;12(1):19. doi: 10.1038/s41523-026-00902-7.
Related trials for Breast Cancer
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingPhase 2
Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
Invasive Mammary Carcinoma, Metastatic Breast Cancer
Not yet recruitingObservational study
Comparison of Reliability, Time Cost, and Participant Comfort of Lymphedema Assessments in Upper Extremity
Lymphedema, Upper Extremity Lymphedema
RecruitingPhase 3
A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)
TNBC - Triple-Negative Breast Cancer
RecruitingPhase 3
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Toralf Reimer, MD, PhD study chair
University Medical Center Rostock
150 sites in 2 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing no axillary surgery versus SLNB and SLNB versus completion ALND in people with Breast Cancer, run by University of Rostock at 150 sites in 2 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 1 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 150 sites in Germany, Austria. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
invasive disease-free survival (IDFS) after breast-conserving surgery (time frame: 5 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02466737, which also lists 6 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 May 2026.